As discussed in the board, longs are willing to tie up dead money in Tilray - sure they miss out on a U.S. cannabis explosion by acquiring US MSOs instead (and opportunities in other sectors for next few years) - but profit in 2026?
Maybe longer.
Tilray Brands, Inc. (NASDAQ:TLRY) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Tilray Brands, Inc. engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Canada, the United States, Europe, Australia, New Zealand, Latin America, and internationally. The US$1.3b market-cap company announced a latest loss of US$1.4b on 31 May 2023 for its most recent financial year result. As path to profitability is the topic on Tilray Brands' investors mind, we've decided to gauge market sentiment. We've put together a brief outline of industry analyst expectations for the company, its year of breakeven and its implied growth rate.
See our latest analysis for Tilray Brands
Tilray Brands is bordering on breakeven, according to the 10 American Pharmaceuticals analysts. They expect the company to post a final loss in 2025, before turning a profit of US$8.9m in 2026. The company is therefore projected to breakeven around 3 years from now. In order to meet this breakeven date, we calculated the rate at which the company must grow year-on-year. It turns out an average annual growth rate of 114% is expected, which is rather optimistic! Should the business grow at a slower rate, it will become profitable at a later date than expected.